• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

3 Reasons Why Caribou Biosciences Is a Screaming Buy in July and Beyond

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Jul 28, 2023 at 10:52: AM
via
  • Caribou's cell therapy programs are among the most advanced that exist.
  • So far, they also appear to be relatively safe and quite effective.
  • The company has more than enough money to reach its next clinical milestones.

article source
 




Top Bottom
Back
Quote